The objective is to explore the potential short and long-term impact of the EXOPULSE Mollii Suit and EXOPULSE Suit on subjects with CP, MS, stroke, fibromyalgia or other neurologic disorders which may cause such types of symptoms, and to identify high responders among the sub-categories of the diagnoses. The primary endpoint will be improvements in the Berg/Pediatric Balance Scale (BBS/PBS) as a measurement of balance and risk of falls.
The observational study (also referred to as the 'registry') is designed to demonstrate the impact of EXOPULSE Mollii Suit and EXOPULSE Suit on relaxation of muscles, muscle activation, local blood circulation and chronic pain relief. The subjects will serve as their own control and the data will be collected before, during and after the treatment period. As the electrical stimulation from the suit usually is above the level of sensation, the study participant will not be blinded to the treatment. To prevent bias, multiple investigators will be collecting the data and only standardized and validated methods will be used. All investigators will be trained on the measurements prior to the registry start. Additionally, all investigators are trained and certified in the EXOPULSE method, and the generic stimulation settings are selected according to a standardized matrix based on the subjects' age and level of impairment. Re-assessments during scheduled visits are part of normal routine and use. The decision whether the subjects will be enrolled in the registry is separated from the subject's decision to use the device.
Study Type
OBSERVATIONAL
Enrollment
200
The registry is designed to demonstrate the impact of EXOPULSE Mollii Suit or EXOPULSE Suit on muscle relaxation, muscle activation, local blood circulation and/or chronic pain relief. The subjects included use the suit for 60 minutes every other day, unless other is specified by the Investigator, in their home environment for up to a maximum of 2 consecutive weeks. Qualitative and quantitative measures will be collected at baseline (T0), after 60 minutes stimulation (T1), after 2 weeks of home use (T2) and during two additional phone calls 1-3 days after the first stimulation session (T1,5) as well as 4 weeks after the first stimulation session (T3).
Ottobock Care Sverige
Bergshamra, Stockholm County, Sweden
RECRUITINGBerg's Balance Scale
Change in balance will be assessed using the 14-item Berg Balance Scale (BBS) which has good psychometric properties in Patients with Multiple Sclerosis (concurrent validity, interrater reliability). The scale rates the balance using 56 points, with higher scores indicating better balance abilities. A score equal to or below 45 is commonly associated with risk of fall across the literature.
Time frame: To be assessed at baseline, after 60 minutes stimulation (T1), and after 2 weeks of home use (T2).
Timed Up and Go (TUG), if applicable for the patient
Change in walking velocity will be assessed with TUG. Patients have to stand up from a chair when they hear the verbal instruction "go", walk a distance of 3 meters, turn around, walk back to the chair and sit down. Timing starts with the verbal instruction "go' and stops when the patients return to the seated position. The score consists of the time taken to complete the test activity, measured in seconds.
Time frame: To be assessed at baseline, immediately after 60 minutes stimulation (T1), and after two weeks of home use (T2).
10 m Walk Test, if applicable for the patient
The 10mWT is used to assess the change in walking speed in meters/second (m/s) over a short distance.
Time frame: To be assessed at baseline, immediately after 60 minutes stimulation (T1), and after two weeks of home use (T2).
Numeric Rating Scale (NRS), if applicable for the patient
The change in pain will be assess with NRS. NRS measures the subjective intensity of pain, where 0=no pain and 10=worst pain imaginable.
Time frame: To be assessed at baseline, immediately after 60 minutes stimulation (T1), after two weeks of home use (T2) and during the two additional phone calls (T1,5 and T3 respectively).
EQ-5D-5L, if applicable for the patient
The change in quality of life will be assessed with EQ-5D, which is an instrument that evaluates the generic quality of life. Designed as a self-completion questionnaire, it embodies two components, a health state description followed by an evaluation.The respondent classifies his or her prevailing state of health by selecting one of three different levels of problem severity within each of five health domains.
Time frame: To be assessed at baseline, after two weeks of home use (T2) and during the two additional phone calls (T1,5 and T3 respectively).
Revised Fibromyalgia Impact Questionnaire (FIQR), if applicable for the patient
The FIQR evaluates the function, overall impact and symptoms of fibromyalgia over the last 7 days. The Fibromyalgia Impact Questionnaire (FIQ) is a well-established and commonly used instrument to evaluate Fibromyalgia patients. The FIQR is a revised version of the FIQ, that has the same 3 domains, i.e. function, overall impact and symptoms. The FIQR also consists of modified function questions as well as questions on memory, tenderness, balance and environmental sensitivity. All questions are graded on a 0-10 numeric scale.
Time frame: To be assessed at baseline, after 2 weeks of home use and during the two additional phone calls (T1,5 and T3 respectively).
Box and Block Test (BBT), if applicable to the patient
The Box and Block Test (BBT) measures unilateral gross manual dexterity in patients with neurological diagnoses. Patients are scored based on the number of blocks transferred from one compartment to the other compartment in 60 seconds
Time frame: To be assessed at baseline, immediately after 60 minutes stimulation (T1) and after two weeks of home use (T2)
12-item Multiple Sclerosis Walking Scale (MSWS-12) , if applicable for the patient
The MSWS-12 is a self-report measure of the impact of MS on the individual's walking ability. It contains 12 questions with Likert-type responses and has a recall period of 2 weeks. The psychometric properties of the MSWS-12 have been extensively evaluated in diverse MS populations in both community and hospital settings, with demonstration of internal consistency, high reliability and validity, and good generalizability. The MSWS-12 is less prone to floor and ceiling effects than are other tools, suggesting adequate assessment of the impact of walking impairment across the range of disability.
Time frame: To be assessed at baseline, after two weeks of home use (T2) and during the two additional phone calls (T1,5 and T3 respectively).
Widespread Pain Index (WPI) , if applicable for the patient
The WPI is based on a standardized questionnaire. Patients are asked in which regions of the body they have experienced pain in the past seven days. In total, the WPI measures pain in 19 defined body regions or pain zones. It is supposed to be used in combination with the Symptom Severity Scale.
Time frame: To be assessed at baseline, immediately after 60 minutes stimulation (T1), after two weeks of home use (T2) and and during the two additional phone calls (T1,5 and T3 respectively).
Symptom Severity Scale (SSS) , if applicable for the patient
SSS calculates severity scores of a number of Fibromyalgia-related symptoms. Together, the WPI and SSS can be used as diagnostic criteria for Fibromyalgia.
Time frame: To be assessed at baseline, after two weeks of home use (T2) and during the two additional phone calls (T1,5 and T3 respectively).
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.